Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Sheena Sharma, Diane Wang, Hoi-Kei Lon, Pooneh Soltantabar, Andrea Viqueira, Akos Czibere, Anne Hickman, Jane Liang White, Mohamed Elmeliegy

Blood (2022) 140 (Supplement 1): 10036–10038.

https://doi.org/10.1182/blood-2022-169836

Published: 2022

Journal Articles

Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study

Hagop M. Kantarjian, MD, Daniel J. DeAngelo, MD, Matthias Stelljes, MD, Michaela Liedtke, MD, Wendy Stock, MD, Nicola Goekbuget, MD, Susan M. O'Brien, MD, Elias J. Jabbour, MD, Tao Wang, PhD, Jane Liang White, ScD, Barbara Sleight, Erik Vandendries, MD PhD, Anjali S. Advani, MD

Blood (2017) 130 (Supplement 1): 2574.

https://doi.org/10.1182/blood.V130.Suppl_1.2574.2574

Published: 2017

Journal Articles

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

Anjali S. Advani, MD, Elias J. Jabbour, MD, Matthias Stelljes, MD, Wendy Stock, MD, Michaela Liedtke, MD, Nicola Goekbuget, MD, Susan M. O'Brien, MD, Jane Liang White, ScD, Tao Wang, PhD, A. Douglas Laird, PhD, Erik Vandendries, MD PhD, Hagop M. Kantarjian, MD

Blood (2017) 130 (Supplement 1): 2557.

https://doi.org/10.1182/blood.V130.Suppl_1.2557.2557

Published: 2017

Journal Articles

Time Course of Venous Thromboembolism Events and Influence of Risk Factors in High Risk Medical Patients,

Russell D Hull, Tazmin Merali, BPharm, MBA, Allan Mills, PharmD, Jane Liang, Nelly Komari, BPharm, MSc

Blood (2011) 118 (21): 4182.

https://doi.org/10.1182/blood.V118.21.4182.4182

Published: 2011

Journal Articles

Rate and Time Course of Thromboembolism Events in Cancer Patients

Russell D Hull, Tazmin Merali, BPharm, MBA, Allan Mills, PharmD, Jane Liang, Nelly Komari, BPharm, MSc

Blood (2011) 118 (21): 4773.

https://doi.org/10.1182/blood.V118.21.4773.4773

Published: 2011

NARROW

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

Time Course of Venous Thromboembolism Events and Influence of Risk Factors in High Risk Medical Patients,

Rate and Time Course of Thromboembolism Events in Cancer Patients

Email alerts

ASH Publications

American Society of Hematology

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

Time Course of Venous Thromboembolism Events and Influence of Risk Factors in High Risk Medical Patients,

Rate and Time Course of Thromboembolism Events in Cancer Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only